Ueland Walker R, Javed Muhammad J, Spinosa Michael, Nguyen Tam, Mirzaie Amin, Amanamba Udochukwu, Neal Dan, Scali Salvatore T, Back Martin R, Huber Thomas S, Upchurch Gilbert R, Shah Samir K
Department of Surgery, University of Florida, Gainesville, FL.
Department of Surgery, University of Florida, Gainesville, FL.
J Vasc Surg. 2025 Jun 3. doi: 10.1016/j.jvs.2025.05.203.
Unplanned hospital readmission following surgery for peripheral arterial disease is among the highest in all diagnosis-related groups. Although previous studies have examined readmissions in certain subgroups, such as for patients undergoing lower extremity bypass, few have examined longer term readmissions for those with the most severe form of peripheral arterial disease, chronic limb-threatening ischemia (CLTI). Among patients with CLTI undergoing revascularization, we sought to outline rates of readmission beyond 30 days up to 1 year and identify patient and procedural characteristics associated with readmission.
We identified patients by Current Procedural Terminology codes from January 6, 2020, to May 25, 2022, and collected demographic, operative, and 1-year outcomes data. We used univariate and multivariable modeling to assess factors associated with hospital readmission.
Of the 247 patients who underwent intervention for CLTI, 130 patients (53%) were readmitted within 1 year, primarily for revascularization-related problems. The most common indications for readmission within 30 days and 1 year were wound infection and tissue breakdown (48.3% and 37.7%, respectively) and new rest pain or tissue loss (13.8% and 20.8%, respectively). The only cause of readmission considered nonmodifiable was undergoing a staged procedure. Overall, 96.6% and 96.9% of readmissions within 30 days and 1 year were potentially modifiable (ie, wound infection and tissue breakdown, new rest pain or tissue loss, graft thrombosis, sepsis, and myocardial infarction). After multivariable adjustment, racial and ethnic minority groups (odds ratio [OR], 2.6; P = .009), female sex (OR, 2.1; P = .031), and tissue loss as an indication (OR, 4.1; P = .0002) were associated with readmission within 30 days. At 1 year, only racial and ethnic minority status (OR, 2.6; P = .007) and a tissue loss indication (OR, 2.1; P = .011) were associated with readmissions. Patient age, comorbidity burden, area deprivation index, and intervention type (endovascular vs open) were not significantly associated with 30-day or 1-year readmissions. Racial and ethnic minority groups (P = .014), female sex (P = .05), acute kidney injury (P = .014), and index hospital length of stay (P = .009) were associated with multiple readmissions. Number of readmissions was not associated with risk of major limb amputation.
Postoperative readmission among patients with CLTI is high and occurs primarily for wound infections and new rest pain or tissue loss. Overall, the majority of readmissions were for potentially modifiable factors. Racial and ethnic minority groups and female patients undergoing revascularization for tissue loss are at greatest risk for readmissions. These data support the investigation of interventions targeting these high-risk populations.
外周动脉疾病手术后的非计划住院再入院率在所有诊断相关组中处于最高水平。尽管先前的研究已经考察了某些亚组的再入院情况,如下肢搭桥手术患者,但很少有研究考察外周动脉疾病最严重形式——慢性肢体威胁性缺血(CLTI)患者的长期再入院情况。在接受血运重建的CLTI患者中,我们试图概述30天至1年的再入院率,并确定与再入院相关的患者和手术特征。
我们通过当前手术操作术语编码识别出2020年1月6日至2022年5月25日期间的患者,并收集人口统计学、手术和1年结局数据。我们使用单变量和多变量模型来评估与住院再入院相关的因素。
在247例接受CLTI干预的患者中,130例(53%)在1年内再次入院,主要是因为血运重建相关问题。在30天和1年内再入院的最常见指征是伤口感染和组织破溃(分别为48.3%和37.7%)以及新出现的静息痛或组织丢失(分别为13.8%和20.8%)。唯一被认为不可改变的再入院原因是接受分期手术。总体而言,30天和1年内再入院的96.6%和96.9%可能是可改变的(即伤口感染和组织破溃、新出现的静息痛或组织丢失、移植物血栓形成、败血症和心肌梗死)。经过多变量调整后,少数种族和族裔群体(比值比[OR],2.6;P = 0.009)、女性(OR,2.1;P = 0.031)以及组织丢失作为指征(OR,4.1;P = 0.0002)与30天内再入院相关。在1年时,只有少数种族和族裔身份(OR,2.6;P = 0.007)和组织丢失指征(OR,2.1;P = 0.011)与再入院相关。患者年龄、合并症负担、地区贫困指数和干预类型(血管内介入与开放手术)与30天或1年再入院无显著相关性。少数种族和族裔群体(P = 0.014)、女性(P = 0.05)、急性肾损伤(P = 0.014)和索引医院住院时间(P = 0.009)与多次再入院相关。再入院次数与大肢体截肢风险无关。
CLTI患者术后再入院率很高,主要发生于伤口感染以及新出现的静息痛或组织丢失。总体而言,大多数再入院是由潜在可改变因素导致的。少数种族和族裔群体以及因组织丢失接受血运重建的女性患者再入院风险最高。这些数据支持针对这些高危人群进行干预研究。